产品
编 号：F744561
分子式：C22H21N7O3
分子量：431.45
分子式：C22H21N7O3
分子量：431.45
产品类型
规格
价格
是否有货
结构图
CAS No: 1380329-87-2
产品详情
生物活性：
Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia.
体内研究：
Gemlapodect (5-15 mg；口服；一天一次持续 6 周) 显著改善儿童期发作性流利性障碍 (COFD) 患者的工作和生活社会功能，显示出生物安全性。Gemlapodect (10 mg/kg；口服；单剂量) 在 9 周龄的 SD 大鼠中不改变葡萄糖耐受性。。Gemlapodect (0.3 mg/kg；口服；一天一次持续 8 天) 在 10 周龄的 SD 大鼠中诱导葡萄糖耐受性轻微改善，空腹血糖无变化，空腹胰岛素降低。Animal Model:Adult male patients with COFD (18-50 years old).
Dosage:5-15 mg.
Administration:Oral gavage; once daily for 6 weeks.
Result:Improved the Stuttering, work, social life, family life and home responsibilities of COFD patients and showed biosafety.
Animal Model:9 weeks or 10 weeks male SD rats.
Dosage:0.3 mg/kg or 10 mg/kg.
Administration:Oral gavage; once daily for 1 or 8 days.
Result:Showed insignificantly change of glucose tolerance in healthy rats.
Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia.
体内研究：
Gemlapodect (5-15 mg；口服；一天一次持续 6 周) 显著改善儿童期发作性流利性障碍 (COFD) 患者的工作和生活社会功能，显示出生物安全性。Gemlapodect (10 mg/kg；口服；单剂量) 在 9 周龄的 SD 大鼠中不改变葡萄糖耐受性。。Gemlapodect (0.3 mg/kg；口服；一天一次持续 8 天) 在 10 周龄的 SD 大鼠中诱导葡萄糖耐受性轻微改善，空腹血糖无变化，空腹胰岛素降低。Animal Model:Adult male patients with COFD (18-50 years old).
Dosage:5-15 mg.
Administration:Oral gavage; once daily for 6 weeks.
Result:Improved the Stuttering, work, social life, family life and home responsibilities of COFD patients and showed biosafety.
Animal Model:9 weeks or 10 weeks male SD rats.
Dosage:0.3 mg/kg or 10 mg/kg.
Administration:Oral gavage; once daily for 1 or 8 days.
Result:Showed insignificantly change of glucose tolerance in healthy rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备